Compare PLTK & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLTK | STOK |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2021 | 2019 |
| Metric | PLTK | STOK |
|---|---|---|
| Price | $3.61 | $32.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $6.61 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 1.4M | 682.6K |
| Earning Date | 02-26-2026 | 03-17-2026 |
| Dividend Yield | ★ 10.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.23 | ★ 0.68 |
| Revenue | ★ $2,726,900,000.00 | $205,632,000.00 |
| Revenue This Year | $9.52 | $428.87 |
| Revenue Next Year | $2.58 | N/A |
| P/E Ratio | ★ $16.18 | $46.68 |
| Revenue Growth | 7.49 | ★ 1128.17 |
| 52 Week Low | $3.31 | $5.35 |
| 52 Week High | $7.55 | $38.69 |
| Indicator | PLTK | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 55.24 |
| Support Level | $3.35 | $30.75 |
| Resistance Level | $3.76 | $34.47 |
| Average True Range (ATR) | 0.16 | 2.01 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 57.83 | 67.31 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. It offers both Mobile and Web-based platforms.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.